📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-13 15:15
0 analysed today
0
Today
133,620
All-time analysed
40,132
Positive
6,284
Negative
79,384
Neutral
7,752
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Jeevan Scientific Re-appoints WTD at Rs 48 Lakh Salary; Subsidiary Posts Rs 1.01 Cr Q1 Loss
Jeevan Scientific Technology Limited has approved the re-appointment of Mrs. Snigdha Mothukuri as Whole Time Director for a 3-year term starting November 2026, with an annual remuneration of Rs 48 lakhs. The board also extended the tenure of Mr. Nageswar Rao Yarllagadda beyond the age of 70. Financially, while the full consolidated results were approved, the auditor's report highlights that subsidiary Nayas Laboratories Private Limited recorded a net loss of Rs 1.01 crore on revenues of Rs 1.37 crore for the quarter ended June 30, 2026. The company's Annual General Meeting is scheduled for September 25, 2026.
Confidence: HIGH
What changedThe company has formalized the continuation of its top leadership for the next 3-5 years and inducted Mr. Kolli Srinivas Rao as a new Independent Director.
Why it mattersLeadership continuity is critical for a small-cap firm, but the significant loss at the subsidiary level (Nayas Laboratories) suggests operational inefficiencies that could drag down overall profitability.
WTD Annual Remuneration: Rs 48,00,000Subsidiary Q1 Revenue: Rs 137.20 lakhsSubsidiary Q1 Net Loss: Rs 100.94 lakhsSubsidiary Loss vs TTM Group Revenue: ~1.6%Promoter Holding (Mar 2026): 30.25%
📅 Short termThe stock may see neutral to slightly cautious movement as the market digests the subsidiary's loss alongside management continuity.
📈 Long termThe company's ability to scale its healthcare research services while turning around loss-making subsidiaries will be the primary driver of long-term value.
⚠ Risk flags
- High burn rate in subsidiary (loss is 73% of its revenue)
- Significant drop in promoter holding (from 38.05% to 30.25% in recent quarters)
- Negative P/E and P/B ratios indicating financial stress
Key Highlights
Re-appointment of Mrs. Snigdha Mothukuri as Whole Time Director for 3 years at Rs 48,00,000 per annum.
Subsidiary Nayas Laboratories reported a net loss of Rs 100.94 lakhs for the quarter ended June 30, 2026.
Subsidiary revenue for Q1 FY27 stood at Rs 137.20 lakhs, indicating a high loss-to-revenue ratio.
Mr. Nageswar Rao Yarllagadda re-appointed as WTD for 3 years from June 2027 at Rs 15,00,000 per annum.
Annual General Meeting (AGM) for FY 2025-26 scheduled for September 25, 2026.
👀 What to Watch
Investors should review the full Q1 FY27 financial statements to assess the impact of the subsidiary's loss on consolidated margins and monitor the recent decline in promoter holding from 38.05% to 30.25%.
Rs 1.01 Cr Q1 Loss at Subsidiary; Jeevan Scientific Approves Director Re-appointments
Jeevan Scientific Technology approved its Q1 FY27 results, highlighting a challenging quarter for its subsidiary, Nayas Laboratories. The subsidiary reported a net loss of Rs 1.01 cr on revenues of Rs 1.37 cr, which is significant given the parent company's total FY26 PAT was only Rs 1.03 cr. The board also proposed the re-appointment of Snigdha Mothukuri as Whole Time Director with a remuneration of Rs 48 lakhs per annum. Additionally, the company scheduled its AGM for September 25, 2026, to seek shareholder approval for these leadership roles.
Confidence: HIGH
What changedThe company has transitioned into the new fiscal year (FY27) with a loss-making subsidiary performance and is seeking to formalize its leadership structure through several director re-appointments.
Why it mattersThe subsidiary's quarterly loss of Rs 1.01 cr nearly equals the company's entire annual profit for FY26 (Rs 1.03 cr), indicating a potential strain on consolidated earnings. High management remuneration and falling promoter stakes are additional points of concern for minority shareholders.
Subsidiary Net Loss (Q1): Rs 100.94 lakhsSubsidiary Revenue (Q1): Rs 137.20 lakhsWTD Remuneration (Snigdha M.): Rs 48,00,000 p.a.Subsidiary Loss vs FY26 PAT: 98.0%Promoter Stake Change (6m): -7.8%
📅 Short termThe stock may face pressure as the market processes the subsidiary's loss and the high management costs relative to the company's small profit base.
📈 Long termThe structural viability depends on turning around the subsidiary and stabilizing promoter holdings, which have seen a sharp decline recently.
⚠ Risk flags
- Subsidiary losses nearly equal to annual consolidated PAT
- High management remuneration relative to net profit
- Significant decline in promoter holding (38% to 30%)
Key Highlights
Subsidiary Nayas Laboratories reported a net loss of Rs 100.94 lakhs for the quarter ended June 30, 2026.
Subsidiary revenue for Q1 FY27 stood at Rs 137.20 lakhs.
Proposed re-appointment of Snigdha Mothukuri as WTD for 3 years at a remuneration of Rs 48,00,000 per annum.
Promoter holding has significantly declined from 38.05% in Dec 2025 to 30.25% in Mar 2026.
Annual General Meeting (AGM) for FY 2025-26 scheduled for September 25, 2026.
👀 What to Watch
Investors should scrutinize the full consolidated financial statement to assess if the parent company's core operations can offset the subsidiary's losses. Monitor the AGM outcomes regarding director remuneration, which appears high relative to the company's annual net profit.
Jeevan Scientific Re-appoints Directors; Subsidiary Reports ₹1.01 Cr Loss in Q1
Jeevan Scientific Technology approved its Q1 FY27 financial results and several key management re-appointments. A critical highlight is the performance of its subsidiary, Nayas Laboratories, which reported a net loss of ₹1.01 Cr on revenue of ₹1.37 Cr for the quarter ended June 2026. The board re-appointed Snigdha Mothukuri as Whole Time Director for 3 years at an annual remuneration of ₹48 lakhs. The company's Annual General Meeting (AGM) is scheduled for September 25, 2026.
Confidence: HIGH
What changedThe company has formalized the continuation of its top leadership for the next 3-5 years and inducted a new Independent Director, Kolli Srinivas Rao.
Why it mattersLeadership continuity is vital for the healthcare research sector; however, the subsidiary's quarterly loss of ₹1.01 Cr is significant compared to the company's TTM PAT of ₹1 Cr, potentially impacting consolidated profitability.
Subsidiary Q1 Net Loss: ₹100.94 lakhsSubsidiary Q1 Revenue: ₹137.20 lakhsWTD Remuneration (Snigdha): ₹48,00,000 per annumPromoter Holding (Mar 2026): 30.25%AGM Date: 25.09.2026
📅 Short termThe stock may see neutral to slightly cautious movement as investors digest the subsidiary's loss against the backdrop of the full Q1 earnings release.
📈 Long termThe company needs to demonstrate a turnaround in its subsidiary operations to improve consolidated margins, especially given the recent drop in promoter holding from 38% to 30%.
⚠ Risk flags
- Subsidiary losses (₹1.01 Cr in Q1)
- Declining promoter holding (38.05% to 30.25% in recent quarters)
- Negative P/E ratio indicating current lack of earnings depth
Key Highlights
Subsidiary Nayas Laboratories reported a net loss of ₹100.94 lakhs for the quarter ended June 30, 2026
Snigdha Mothukuri re-appointed as Whole Time Director for 3 years at ₹48,00,000 per annum
Nageswar Rao Yarllagadda re-appointed as Whole Time Director for 3 years at ₹15,00,000 per annum
Subsidiary revenue for Q1 FY27 stood at ₹137.20 lakhs
Annual General Meeting scheduled for September 25, 2026, via video conferencing
👀 What to Watch
Investors should review the full Q1 FY27 standalone results to determine if the parent company's operations are sufficient to cover the subsidiary's losses. Monitor the upcoming AGM for shareholder approval of director remunerations and leadership continuity.
18.8% Capacity Expansion: Jeevan Scientific Receives CDSCO Approval for Hyderabad BA/BE Center
Jeevan Scientific Technology has received CDSCO approval to increase its bed capacity at the Hyderabad Bioavailability/Bioequivalence (BA/BE) center. The total capacity will rise from 138 beds (132 general + 6 ICU) to 164 beds (156 general + 8 ICU), representing an 18.8% increase in operational infrastructure. This approval follows a successful regulatory inspection conducted on June 24, 2026. Given the company's TTM revenue of Rs 62 Cr and recent return to profitability in FY26 (PAT Rs 1.03 Cr), this expansion provides a clear pathway for volume-driven growth.
Confidence: HIGH
What changedThe company has secured formal regulatory approval to expand its clinical study infrastructure after a successful CDSCO inspection.
Why it mattersFor a clinical research organization, bed capacity is a primary constraint on revenue; this expansion allows the company to handle more concurrent studies and larger study cohorts.
Existing Total Beds: 138New Total Beds: 164Capacity Increase (%): 18.8%TTM Revenue: Rs 62 CrInspection Date: June 24, 2026
📅 Short termThe news is likely to be viewed positively by the market as it removes regulatory uncertainty and provides a tangible catalyst for growth in the current fiscal year.
📈 Long termThis expansion aligns with the company's recent turnaround from losses in FY25 to profit in FY26, suggesting a structural scaling of their clinical research business.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Promoter holding decreased from 38.05% to 30.25% in the March 2026 quarter
- Execution risk in maintaining high utilization rates for the new capacity
Key Highlights
Total bed capacity increased from 138 to 164, a net addition of 26 beds
ICU bed capacity enhanced by 33%, moving from 6 to 8 beds
CDSCO regulatory inspection successfully cleared on June 24, 2026
Expansion located at the existing Balanagar, Hyderabad facility
Capacity boost of 18.8% directly supports higher volume for BA/BE studies
👀 What to Watch
Investors should monitor the revenue growth in the clinical research segment over the next two quarters to verify if the 18.8% capacity increase leads to a corresponding improvement in the top line and OPM (currently 15.9%).
Zero 483s: Jeevan Scientific Successfully Completes USFDA Inspection of Hyderabad Facility
Jeevan Scientific Technology (JSTL) has successfully completed a USFDA inspection of its Bioanalytical Facility in Hyderabad with zero observations (No Form 483). The inspection, conducted from July 20 to July 24, 2026, reviewed BA/BE studies and operational systems. This clean report is a significant regulatory milestone for a company with TTM revenue of Rs 62 Cr, as it validates their compliance for international markets. The successful audit ensures the facility can continue supporting global clinical research projects without regulatory hurdles.
Confidence: HIGH
What changedThe company's primary bioanalytical facility received a clean audit report from the USFDA with no deficiencies noted.
Why it mattersFor a small-cap Contract Research Organization (CRO), a 'Zero 483' status is a major credibility booster that reduces the risk of business disruption and enables the company to bid for high-value international BA/BE studies.
Inspection Duration: 5 daysObservations: Zero 483sTTM Revenue: Rs 62 CrMar 2026 Quarterly Revenue: Rs 21.29 CrPromoter Holding (Mar 2026): 30.25%
📅 Short termThe stock is likely to react positively as the 'Zero 483' status removes regulatory uncertainty regarding its Hyderabad operations.
📈 Long termThis clearance strengthens JSTL's position in the global clinical research market, supporting its recent trajectory of revenue growth (from Rs 46.84 Cr in FY25 to TTM Rs 62 Cr).
⚠ Risk flags
- Significant drop in promoter holding from 38.05% to 30.25% in the most recent quarter
- Small scale of operations with TTM PAT of only Rs 1 Cr
Key Highlights
Inspection concluded with Zero 483 observations, indicating full compliance with USFDA standards.
The audit was conducted over a 5-day period from July 20, 2026, to July 24, 2026.
Facility inspected is the Bioanalytical Facility located at Manikonda, Hyderabad.
Company reported a significant revenue jump to Rs 21.29 Cr in Mar 2026 vs Rs 8.8 Cr in Jun 2025, making regulatory stability crucial.
👀 What to Watch
Monitor if this regulatory clearance translates into new contract wins from international pharmaceutical clients. Investors should also watch the promoter holding trend, which recently decreased from 38.05% to 30.25%.
